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 
Abstract— With the increasing number of people living 
with Alzheimer’s disease (AD), there is a need for low-cost 
and easy to use methods to detect AD early to facilitate 
access to appropriate care pathways. Neuroimaging 
biomarkers (such as those based on PET and MRI) and 
biochemical biomarkers (such as those based on CSF) are 
recommended by international guidelines to facilitate 
diagnosis.  However, neuroimaging is expensive and may 
not be widely available and CSF testing is invasive.  Blood-
based biomarkers offer the potential for the development of 
a low-cost and more time efficient tool to detect AD to 
complement CSF and neuroimaging as blood is much easier 
to obtain.  
Although no single blood biomarker is yet able to detect 
AD, combinations of biomarkers (also called panels) have 
shown good results. However, a large number of biomarkers 
are often needed to achieve a satisfactory detection 
performance. In addition, it is difficult to reproduce reported 
results within and across different study cohorts because of 
data overfitting and lack of access to the datasets used in the 
studies.  In this study, our focus is to identify an optimum 
panel (in terms of the least number of blood biomarkers to 
meet the specified diagnostic performance of 80% sensitivity 
and specificity) based on a widely accessible data set, and to 
demonstrate a testing methodology that reinforces 
reproducibility of results.  Realizing a panel with reduced 
number of markers will have significant impact on the 
complexity and cost of diagnosis and potential development 
of cost-effective point of care devices.  
 
Index Terms– AD, Biomarkers, ADNI, Machine learning 
I. INTRODUCTION 
Alzheimer’s disease (AD) is the leading disease of 
neurodegeneration in the older population. It is the cause of 
more than 60% of all dementia cases [1]. The disease is 
clinically manifest in the form of progressive cognitive and, 
subsequently, functional decline to a degree that the 
sufferer’s daily living is impaired. More than 47 million 
people are estimated to suffer dementia worldwide, with an 
expected increase to 131 million by 2050 [2]. The economic 
burden of dementia is enormous with the annual global 
estimated cost above US818 billion and expected to hit a 
trillion dollars in 2018 [2]. There is a delay of between 3-10 
years between symptoms onset and diagnosis of AD, by 
which time irreversible cell damage would have occurred. 
There is no cure for AD, but new drugs and therapies are 
being developed which may slow, halt or reverse the disease 
 
 
processes. Notwithstanding, a significant proportion of 
dementia patients are undiagnosed as a result of inadequate 
access to diagnosis. Of those that receive a dementia 
diagnosis, a significant number may have received it late, 
when extensive cell damage would have occurred and when 
treatments are less effective. In view of this, it is thought that 
providing accessible early diagnosis, may decrease the 
burden of dementia, facilitate access to evidence based 
pathway to treatment. It may also facilitate planning and 
timely receipt of suitable health and social care services [2].  
Traditionally, AD was only diagnosed at the clinically 
symptomatic stage by neuropsychological examination 
alone. However, research in the last decades has redefined 
the concept of AD as a clinical-biological entity [3, 4]. This 
conceptual framework has led to the introduction and 
utilization of biomarkers in AD assessment. A biomarker is 
a parameter (physiological, biochemical, or anatomic) that 
can be objectively measured and evaluated in vivo as an 
indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic 
intervention [5, 6]. Recommended biomarkers of AD have 
been incorporated as supportive evidence in AD diagnostic 
criteria. These biomarkers are extracted from amyloid 
positron emission tomography (PET) and cerebrospinal fluid 
(CSF) analysis. However, CSF is obtained through lumbar 
puncture, which is widely considered as an invasive 
procedure, and neuroimaging tests are expensive.  
Research studies are investigating several putative AD 
biomarkers, including ones found in peripheral blood. These 
areas are receiving closer research attention as huge efforts 
target identifying and validating AD biomarkers that are 
minimally invasive, simple to use and cost-effective, and 
able to reliably discriminate target population in the light of 
the disease [7, 8]. Blood-based biomarkers may be more cost 
and time efficient to assess AD. AD blood biomarkers have 
shown promising results and are anticipated to have the 
potential to meet these targets and thus foster improved 
accessibility to diagnosis. However, no single blood 
biomarker of AD is yet able to provide acceptable diagnostic 
performance in terms of sensitivity and specificity, only a 
panel of blood biomarkers may achieve such performance. 
Consequently, a number of research studies have 
investigated AD diagnostic performance of some blood 
biomarker panels. Ray et al. [9] identified an 18-biomarker 
panel that attained sensitivity and specificity values of 90% 
and 88% respectively, while a 30-biomarker panel was 
identified by  O’Bryant et al. [10], which  achieved 
sensitivity and specificity values of 94% and 84%, 
respectively.  Daniel et al. [11] identified 5 to 15 biomarker 
panels that detected AD with 74% sensitivity and 85% 
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specificity. Using Alzheimer’s Neuroimaging Initiative 
(ADNI) cohort, Doecke et al. [12] identified an 18-marker 
panel that identified AD with sensitivity and specificity 
values of 80%. A study by Guo et al.’s [13] obtained 
sensitivity and specificity values of 89.36% and 79.17%. 
Recently, Jammeh et al. [14] identified a panel of six blood 
biomarkers that was able to detect AD with sensitivity and 
specificity values of 85.4% and 78.6%, respectively.  
Despite the progress, some of the identified panels of 
blood biomarkers consist of a large number of biomarkers, 
or have not met acceptable performance specification. 
Furthermore, there are difficulties with replicating results, 
due to many factors such as overfitting in model 
development [15]. In addition, some of the studies cannot be 
replicated because panels were identified using datasets that 
are difficult to access or are based on biomarkers that are not 
found in accessible databases. These challenges impede 
continued investigation of the utility of blood biomarkers in 
AD diagnosis and progress in identifying blood biomarker 
panels with clinical utility. 
The main objectives of this research are to (1) identify an 
optimum panel of adequately cross-validated blood 
biomarkers of AD that can detect Alzheimer’s with 
acceptable diagnostic performance of at least 80% sensitivity 
and specificity values [8], using widely accessible and well 
characterized blood proteomic dataset and (2) demonstrate a 
methodological framework of testing the overall reliability 
of blood biomarker panels to facilitate replication of results. 
It is noteworthy that realizing a minimum number of 
biomarkers that provide high and reliable diagnostic 
performance may result in reduced complexity and cost of 
implementation of point of care diagnostic devices for AD.  
II. METHODS 
The methodology that was adopted in this study is illustrated 
in Figure 1. 
A. Clinical data 
Data used in this study were obtained from ADNI 
(http://adni.loni.ucla.edu). ADNI phase 1 (ADNI1) baseline 
quality-controlled data of the concentration of 146 blood 
plasma proteins/biomarkers derived from a cohort of 112 
Alzheimer’s disease patients and 58 healthy controls were 
downloaded alongside the demographic and clinical status of 
the subjects. The Alzheimer’s disease subjects used in this 
study were at the dementia stage of the disease. Summary of 
the demographics of the subjects is shown in TABLE I.  
Data from four of the Alzheimer’s disease subjects, 
including 3 that were diagnosed as possible Alzheimer’s 
disease and 1 diagnosed with only mild level of confidence, 
were excluded from our study, leaving 108 AD subjects. The 
most cross-validated putative blood biomarkers of AD were 
identified from the literature, and the ones available in 
ADNI were used to characterize AD and healthy control 
(HC) clinical groups.  
B. Statistical analysis 
The probability distribution of each of the markers used 
in characterizing the AD patients and HCs was normal and 
their differential abundance between the two clinical groups 
was analyzed using Student’s t-test. Only the ones with 
statistically significant difference (p ≤ 0.05) were used as 
candidates for the identification of biomarker panels. 
C. Computation of possible biomarker panels  
 A brute force approach was used in making the choice of 
biomarker combinations to consider. All the possible 
combinations, also called panels, (consisting of 2, 3, 4, and 5 
biomarkers) of the markers selected after the statistical 
analysis were computed. Each of the possible panels was 
used for the classification procedure described in Section D. 
This method of panel identification is different from the usual 
methods seen in blood biomarker studies, where some sort of 
reductionist approach is often implemented. The danger with 
such methods is that some useful biomarker panels may be 
missed. 
D. Classification and biomarker panel selection 
Support vector machine (SVM) supervised machine 
learning algorithm implemented in MATLAB (R2017b) was 
used to identify an optimum panel of biomarkers that met the 
desired performance.  SVM is a machine learning algorithm 
that creates a hyperplane between data sets to indicate the 
class to which they belong. It defines the decision boundary 
with only a subset of the training points, called the support 
vectors. SVM has been extensively applied in Alzheimer’s 
research [16, 17]. 
The classifier algorithm was trained and tested with each 
of the possible panels of markers described in Section C 
using 10-fold cross-validation technique. This technique 
randomly divides the applied dataset into 10 sub-datasets, 
and ensures that each subset is used for both training and 
testing. 10-fold cross-validation, implements a mechanism to 
avoid model overfitting.  Apolipoprotein ε4 (APOE4) 
genotype was used as a covariate to the biomarkers, as it has 
been reported as one of the major clinical AD risk factors 
[18].The training and testing of a model with each panel was 
repeated five times and the performance metrics recorded per 
time. Performance was measured in terms of sensitivity, 
specificity, accuracy and area under the operating curve 
(AUC). The panel that showed high consistency in 
performance with sensitivity and specificity values greater 
than 80%, was selected for reliability test.  
E. Test of reliability 
In the reliability test phase, the 10-fold cross-validation 
was iterated one thousand times (with the training and testing 
subsets internally randomized each time) and the average 
performance recorded. The reason was to thoroughly 
investigate the robustness of the selected panel in detecting 
AD across the entire dataset. In addition, the percentage of 
the times that the panel achieved sensitivity and specificity of 
not less than 80% (i.e., success rate) was calculated. The 
panel with high success rate was selected as the final panel. 
Earlier studies failed to account for success rate. However, it 
is of a critical importance so as to demonstrate the reliability 
of the panel’s reported performance.   
III. RESULTS 
From the review of literature, 173 blood-based 
biomarkers of AD (excluding groups of microRNAs) were 
identified from 54 studies, from which 40 were cross-
  
validated. However, only 31 of these markers were available 
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Figure 1. Description of methodology 
Of the 31 proteins, only 14 that are listed in TABLE II 
showed significant difference between the AD and HC 
subjects. There were 3,458 possible candidate biomarker 
panels from the 14 shown in TABLE II. Each of the possible 
panels went through the learning procedure described in 
Section D. The machine learning algorithm identified a panel 
of five markers which includes Alpha-1 microglobulin 
(A1M), Alpha-2 macroglobulin (A2M), Complement C3 
(C3), Immunoglobulin M (IgM), and Tenascin C (TNC). This 
panel detected AD with an average performance of 86.5%, 
82.1%, 85% and 0.89 sensitivity, specificity, accuracy, and 
AUC, respectively. It achieved a success rate of 77.8% in the 
reliability test. This demonstrates that it is not sufficient to 
report the average or maximum performance of a panel in 
blood biomarker research but in addition, there is need to test 
and report its reliability across the entire dataset used in the 
study, as we have demonstrated in this paper.  

















% APOE4+ 68.5 8.6 
 
 
AD indicates Alzheimer disease;  
HC, healthy controls;  
SD, standard deviation;  
APOE4+, Apolipoprotein ε4 positive genotype 
 
 
TABLE II.  LIST OF EXAMINED MARKERS AND IDENTIFIED PANEL 
Candidate markers Identified 5-marker 
panel 
Alpha-1 microglobulin Alpha-1 microglobulin 
Alpha-2 macroglobulin Alpha-2 macroglobulin 
Alpha-1 antitrypsin Complement C3 
Apolipoprotein E Immunoglobulin M 
Beta-2 microglobulin Tenascin C 
Brain natriuretic 
peptide   
 
Complement C3  
Eotaxin-3  






Pancreatic polypeptide  
Tenascin C  
Vascular cell adhesion 
molecule-1 
 
The method will aid reveal the true strength of the 
identified panel, improve the chances of replicating the 
reported performance and facilitate further refinements of the 
existing panels. 
IV. DISCUSSION 
In this study, we identified 5-biomarker panel (A1M, 
A2M, C3, IgM and TNC) for the diagnosis of AD in ADNI 
cohort, using APOE genotype as an additional feature, and 
thoroughly examined the robustness of the panel. The five 
biomarkers are well cross-validated candidate markers of AD 
across different cohorts. A1M is a protein involved in 
inflammatory response [19] that has also been identified as a 
plasma marker of brain atrophy in Alzheimer’s disease [20]. 
The role of A2M in AD has been extensively researched; 
Bauer et al. [21] showed that A2M was present in amyloid 
plaques. Since then, it has further been linked to blood–brain 
barrier damage [22], hippocampal metabolism in early 
Alzheimer’s disease [23] and neuronal injury [24]. 
Complement C3 has been identified as a marker of brain 
atrophy in AD [20] and cerebral amyloid in non-demented 
elderly [25]. IGM has been identified as blood protein marker 
of neocortical Amyloid-beta burden [26, 27]. 
TNC is an extracellular glycoprotein that has been linked to 
different biological processes, including inflammation and 
angiogenesis, which have association with AD [28]. Both 
IGM and TNC have been linked to apolipoprotein E 
genotype as well [29]. 
V. CONCLUSION 
In summary, this piece of work further validates the 
utility of blood-based markers in diagnosing Alzheimer’s 
disease and that reliable diagnosis with only a few number of 
biomarkers may be feasible and thus, widely accessible and 
routine diagnosis of Alzheimer’s may be possible.  
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